<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Trimethadione</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00347</strong>&#160; (APRD00315)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From <span class="caps">AMA</span> Drug Evaluations Annual, 1994, p378)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00347/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00347/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00347.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00347.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00347.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00347.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00347.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00347">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Trimethadion</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Ph. Eur. 7</td></tr><tr><td>Trim&#233;thadione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCF</td></tr><tr><td>Trimethadionum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Ph. Eur. 7, Ph. Int. 4</td></tr><tr><td>Trimethinum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Troxidone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Minoale</td><td>Dainippon Sumitomo</td></tr><tr><td>Tridione</td><td>Abbott</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li></ul></td></tr><tr><th>CAS number</th><td>127-48-0</td></tr><tr><th>Weight</th><td>Average: 143.1406<br>Monoisotopic: 143.058243159</td></tr><tr><th>Chemical Formula</th><td>C<sub>6</sub>H<sub>9</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>IRYJRGCIQBGHIV-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">trimethyl-1,3-oxazolidine-2,4-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN1C(=O)OC(C)(C)C1=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00347.gif?1265922770">show</a>(7.69 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azolidines</td></tr><tr><th>Subclass</th><td>Oxazolidines</td></tr><tr><th>Direct parent</th><td>Oxazolidinediones</td></tr><tr><th>Alternative parents</th><td>N-substituted Carboxylic Acid Imides; Tertiary Carboxylic Acid Amides; Tertiary Amines; Carbamic Acids and Derivatives; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>carboxylic acid imide, n-substituted; tertiary carboxylic acid amide; carbamic acid derivative; carboxamide group; tertiary amine; polyamine; carboxylic acid derivative; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the oxazolidinediones. These are compound containing an oxazolidine ring which bears two ketones.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in the control of absence (petit mal) seizures that are refractory to treatment with other medications.</td></tr><tr><th>Pharmacodynamics</th><td>Paramethadione and trimethadione are anticonvulsants indicated in the control of absence (petit mal) seizures that are refractory to treatment with other medications. Dione anticonvulsants are used in the treatment of epilepsy. They act on the central nervous system (CNS) to reduce the number of seizures.</td></tr><tr><th>Mechanism of action</th><td>Dione anticonvulsants reduce T-type calcium currents in thalamic neurons, including thalamic relay neurons. It does so via the inhibition of voltage dependent T-type calcium channels. This raises the threshold for repetitive activity in the thalamus, and inhibits corticothalamic transmission. Thus, the abnormal thalamocortical rhythmicity, which is thought to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram(EEG) with absence seizures, is dampened.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>90%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Trimethadione</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003533" target="_blank">Cytochrome P450 2E1</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00451">dimethadione</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/460">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include clumsiness or unsteadiness, coma, dizziness (severe), drowsiness (severe), nausea (severe), and problems with vision.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9954</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9479</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5287</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8304</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6154</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9503</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8289</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5881</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9694</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9361</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6493
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8515
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7859
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8563 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9961
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9775
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abbott laboratories pharmaceutical products div</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00822">Disulfiram</a></td><td>Disulfiram, a strong CYP2E1 inhibitor, may decrease the metabolism and clearance of Trimethadione, a CYP2E1 substrate. Consider alternate therapy or monitor for changes in Trimethadione therapeutic and adverse effects if Disulfiram is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Trimethadione, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>